ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 0654

Comparison of Cardiovascular Risk in Patients with Systemic Sclerosis and the General Population
Abstract Number: 0655

A Novel Association Between Lipodermatosclerosis and Key Vascular Outcomes in Systemic Sclerosis
Abstract Number: 0656

Concordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression
Abstract Number: 0657

The Value of the Six-Minute Walk Test in Detecting Cardiopulmonary Involvement in Patients with Systemic Sclerosis
Abstract Number: 0658

Evaluating the Associations Between Autonomic Dysfunction, Clinical Phenotype and Gastrointestinal Transit in Patients with Systemic Sclerosis
Abstract Number: 0659

Cigarette Exposure in Systemic Sclerosis: Impact on Autoantibody Expression and Disease Manifestations: Analysis of the EUSTAR Cohort
Abstract Number: 0660

Cigarette Smoking Increases the Risk of All-Cause Mortality in Male Patients with Systemic Sclerosis: An Analysis of the EUSTAR Cohort
Abstract Number: 0661

Assessment of Systemic Sclerosis-Associated Myocarditis: A Single Center Case Series Study
Abstract Number: 0662

Changes in Treatment Patterns and Their Influence on the Outcome of Systemic Sclerosis-interstitial Lung Disease (SSc-ILD) Patients: An EUSTAR Analysis
Abstract Number: 0663

Vaccine-Preventable Diseases in Hospitalized Patients with Systemic Sclerosis: A Nationwide Cohort Analysis
Abstract Number: 0664

Quantitative Hand Held Dynamometry to Assess Muscle Strength in Scleroderma Associated Myopathy
Abstract Number: 0665

A Descriptive Study of Disease Characterisics of SSc Patients with the U2RNP Autoantibody
Abstract Number: 0666

Troponin I Levels in Systemic Sclerosis Patients with Myocardial Involvement
Abstract Number: 0667

The Risk of Stroke and Myocardial Infarction in Systemic Sclerosis: A Population-based Study
Abstract Number: 0668

Increased Risk of Cancer in Patients with Systemic Sclerosis: A Population-based Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].